No Data
No Data
Jingxin Pharmaceutical (002020): Finished drugs are stabilizing and increasing the dosage of new drugs for insomnia can be expected
The impact of the company's generic drug collection is basically clear, and performance is expected to grow steadily. The company promotes levetiracetam tablets, sertraline hydrochloride tablets, dispersible tablets, and salt by establishing a “split line” marketing model centered on the three major channels of neuropsychiatric, cardiovascular, and digestive systems
Pacific released a research report on April 25 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating, and the target price was 18.42 yuan. The main reasons for the rating include: 1) Q1 revenue growth rate was steady, and performance e
Pacific released a research report on April 25 stating that it gave Jingxin Pharmaceutical (002020.SZ) a purchase rating, and the target price was 18.42 yuan. The main reasons for the rating include: 1) Q1 revenue growth rate was steady, and performance exceeded expectations; 2) gross margin increased and profitability improved; 3) Digitalini achieved commercialization and continued implementation of the innovation pipeline. (Mainichi Keizai Shimbun)
Ping An Securities released a research report on April 24 stating that it gave Jingxin Pharmaceutical (002020.SZ) a recommended rating. The main reasons for the rating include: 1) the company's 24Q1 revenue side resumed relatively rapid growth, and the pr
Ping An Securities released a research report on April 24 stating that it gave Jingxin Pharmaceutical (002020.SZ) a recommended rating. The main reasons for the rating include: 1) the company's 24Q1 revenue side resumed relatively rapid growth, and the profit side returned to a long-term growth trajectory; 2) the adjustment of the finished drug sales structure showed initial results, and product profitability was gradually optimized; 3) the company had plenty of cash on hand, and multiple mental nerves continued to advance in the research pipeline. (Mainichi Keizai Shimbun)
Jingxin Pharmaceutical (002020.SZ): Net profit of 171 million yuan in the first quarter increased 13.23% year-on-year
Gelonghui, April 23 | Jingxin Pharmaceutical (002020.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,061 million yuan, up 10.44% year on year; net profit attributable to shareholders of listed companies was 171 million yuan, up 13.23% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 157 million yuan, up 14.30% year on year; basic earnings per share were 0.20 yuan.
Express News | Jingxin Pharmaceutical reached a strategic cooperation with Kyushu Pharmaceutical Group
Jingxin Pharmaceutical: Jingjianyuan integrated artificial large blood vessel completed the first case enrollment
Recently, the “integrated artificial large blood vessel” product developed by Zhejiang Jingjianyuan Medical Technology Co., Ltd., a wholly-owned subsidiary of Jingxin Pharmaceutical, entered the small-sample human trial stage, and completed the first patient implantation of Stanford A aortic dissection surgery at Wuhan Asian Heart Hospital. The operation progressed smoothly, the patient recovered well after surgery, and the operator affirmed the product's performance. According to reports, an integrated artificial large blood vessel is a medical device covering a novel design concept. It has the characteristics of no stitches, easy operation, short cycle stop time at deep and low temperature, and reduced risk of complications.
No Data